TABLE 2.
Examination of Factors Related to RAPID3 Score Trajectory as Measured by a Clinically Important Improvement (≥3.8 Points) or Being Low Severity/Near Remission at 6 Months
| Total N = 312 (100.0) | Clinically important improvement ≥ 3.8 points | P value | Low severity/near remission | P value | ||||
|---|---|---|---|---|---|---|---|---|
| No N = 165 (52.9) | Yes N = 147 (47.1) | No N = 207 (66.3) | Yes N = 105 (33.7) | |||||
| Baseline RAPID3 severity, n (%) | High | 195 | 84 (43.1) | 111 (56.9) | 157 (80.5) | 38 (19.5) | ||
| Moderate | 77 | 42 (54.5) | 35 (45.5) | 43 (55.8) | 34 (44.2) | |||
| Low/near remission | 40 | 39 (97.5) | 1 (2.5) | <0.0001 | 7 (17.5) | 33 (82.5) | <0.0001 | |
| Age group, n (%), years | 18-34 | 42 | 22 (52.4) | 20 (47.6) | 27 (64.3) | 15 (35.7) | ||
| 35-49 | 87 | 44 (50.6) | 43 (49.4) | 60 (69.0) | 27 (31.0) | |||
| 50-64 | 162 | 89 (54.9) | 73 (45.1) | 107 (66.0) | 55 (34.0) | |||
| 65+ | 21 | 10 (47.6) | 11 (52.4) | 0.87 | 13 (61.9) | 8 (38.1) | 0.91 | |
| Gender, n (%) | Female | 252 | 131 (52.0) | 121 (48.0) | 174 (69.0) | 78 (31.0) | ||
| Male | 60 | 34 (56.7) | 26 (43.3) | 0.51 | 33 (55.0) | 27 (45.0) | 0.039 | |
| Payer, n (%) | Commercial | 171 | 84 (49.1) | 87 (50.9) | 99 (57.9) | 72 (42.1) | ||
| Medicaid | 116 | 69 (59.5) | 47 (40.5) | 88 (75.9) | 28 (24.1) | |||
| Medicare | 25 | 12 (48.0) | 13 (52.0) | 0.20 | 20 (80.0) | 5 (20.0) | 0.022 | |
| Corticosteroid use, n (%) | Baseline | 110 | 52 (47.3) | 58 (52.7) | 0.14 | 71 (65.0) | 39 (35.0) | 0.62 |
| Follow-up | 72 | 33 (45.8) | 39 (54.2) | 0.17 | 50 (69.4) | 22 (30.6) | 0.53 | |
| Methotrexate use, n (%) | Baseline | 138 | 77 (55.8) | 61 (44.2) | 0.36 | 92 (66.7) | 46 (33.3) | 0.92 |
| Follow-up | 56 | 32 (57.1) | 24 (42.9) | 0.48 | 41 (73.2) | 15 (26.8) | 0.23 | |
| Other DMARD use, n (%) | Baseline | 111 | 49 (44.1) | 62 (55.9) | 0.022 | 74 (66.7) | 37 (33.3) | 0.93 |
| Follow-up | 46 | 24 (52.2) | 22 (47.8) | 0.92 | 34 (73.9) | 12 (26.1) | 0.24 | |
| Medication change, n (%) | 62 | 41 (66.1) | 21 (33.9) | 0.020 | 55 (88.7) | 7 (11.3) | <0.0001 | |
| PDC, median (IQR) | 97 (87, 100) | 96 (87, 100) | 98 (89, 100) | 0.16 | 96 (82, 100) | 99 (91, 100) | 0.012 | |
| Adherent: PDC ≥ 80%, n (%) | 260 | 136 (52.3) | 124 (47.7) | 0.65 | 162 (62.3) | 98 (37.7) | 0.0007 | |
| TM care interactions, n (%) | Opt in to full TM care | 248 | 122 (49.2) | 126 (50.8) | 152 (61.3) | 96 (38.7) | ||
| Opt out of full TM care | 64 | 43 (67.2) | 21 (32.8) | 0.010 | 55 (85.9) | 9 (14.1) | 0.0002 | |
| RA goals met | 93 | 38 (40.9) | 55 (59.1) | 0.0056 | 35 (37.6) | 58 (62.4) | <0.0001 | |
| Referral to health coach | 6 | 5 (83.3) | 1 (16.7) | 0.13 | 6 (100.0) | 0 (0.0) | 0.10 | |
| Side-effect monitoring | 32 | 19 (59.4) | 13 (40.6) | 0.44 | 23 (71.9) | 9 (28.1) | 0.48 | |
| Pharmacist intervention | 44 | 26 (59.1) | 18 (40.9) | 0.37 | 34 (77.3) | 10 (22.7) | 0.098 | |
DMARD = disease-modifying antirheumatic drug; PDC = proportion of days covered; RA = rheumatoid arthritis; RAPID3 = Routine Assessment of Patient Index Data 3; TM = therapy management.